Benefits of Dapagliflozin in HFmrEF/HFpEF Not Modified by AF at Baseline
Researchers evaluated if atrial fibrillation affects dapagliflozin therapy in patients with heart failure with preserved ejection fraction.
Sheila Jacobs
Contributing Writer https://www.endocrinologyadvisor.com
Sheila Jacobs is the president of STJ Editorial Services. For more than 25 years, Sheila has been providing writing, fact-checking, and editorial services to numerous clients in the medical education, promotional, and managed care arenas, from the conceptual stage through completion of the final editorial product. Her focus has been in a diverse array of therapeutic areas.
